204 related articles for article (PubMed ID: 27588129)
41. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
42. An indispensable role of TAZ in anoikis resistance promoted by OTUB1 deubiquitinating enzyme in basal-like triple-negative breast cancer cells.
Nakagawa H; Higurashi M; Ishikawa F; Mori K; Shibanuma M
Biochem Biophys Res Commun; 2023 Mar; 649():1-9. PubMed ID: 36738577
[TBL] [Abstract][Full Text] [Related]
43. Knockdown of YAP/TAZ Inhibits the Migration and Invasion of Fibroblast Synovial Cells in Rheumatoid Arthritis by Regulating Autophagy.
Zhou W; Shen Q; Wang H; Yang J; Zhang C; Deng Z; Wu K; Zhou Y; Zeng J; Zhang Y; Shen W
J Immunol Res; 2020; 2020():9510594. PubMed ID: 33145365
[TBL] [Abstract][Full Text] [Related]
44. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
[TBL] [Abstract][Full Text] [Related]
45. Wnt5A and TGFβ1 Converges through YAP1 Activity and Integrin Alpha v Up-Regulation Promoting Epithelial to Mesenchymal Transition in Ovarian Cancer Cells and Mesothelial Cell Activation.
Dehghani-Ghobadi Z; Sheikh Hasani S; Arefian E; Hossein G
Cells; 2022 Jan; 11(2):. PubMed ID: 35053353
[TBL] [Abstract][Full Text] [Related]
46. FTO promotes cervical cancer cell proliferation, colony formation, migration and invasion via the regulation of the BMP4/Hippo/YAP1/TAZ pathway.
Huang J; Yang J; Zhang Y; Lu D; Dai Y
Exp Cell Res; 2023 Jun; 427(1):113585. PubMed ID: 37030332
[TBL] [Abstract][Full Text] [Related]
47. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma.
Xiao H; Jiang N; Zhou B; Liu Q; Du C
Cancer Sci; 2015 Feb; 106(2):151-9. PubMed ID: 25495189
[TBL] [Abstract][Full Text] [Related]
48. Hippo/TEAD4 signaling pathway as a potential target for the treatment of breast cancer.
Wu Y; Li M; Lin J; Hu C
Oncol Lett; 2021 Apr; 21(4):313. PubMed ID: 33692845
[TBL] [Abstract][Full Text] [Related]
49. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
[TBL] [Abstract][Full Text] [Related]
50. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer.
Li Z; Wang Y; Zhu Y; Yuan C; Wang D; Zhang W; Qi B; Qiu J; Song X; Ye J; Wu H; Jiang H; Liu L; Zhang Y; Song LN; Yang J; Cheng J
Mol Oncol; 2015 Jun; 9(6):1091-105. PubMed ID: 25704916
[TBL] [Abstract][Full Text] [Related]
51. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
52. The Hippo Signaling Core Components YAP and TAZ as New Prognostic Factors in Lung Cancer.
Jiang Y; Xie WJ; Chen RW; You WW; Ye WL; Chen H; Chen WX; Xu JP
Front Surg; 2022; 9():813123. PubMed ID: 35388363
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of TAZ impairs the migration ability of melanoma cells.
Zhang H; Tu L; Ma Z; Lin Y; Tan Q
Open Life Sci; 2023; 18(1):20220633. PubMed ID: 37360787
[TBL] [Abstract][Full Text] [Related]
54. Molecular Mechanism of Hippo-YAP1/TAZ Pathway in Heart Development, Disease, and Regeneration.
Chen X; Li Y; Luo J; Hou N
Front Physiol; 2020; 11():389. PubMed ID: 32390875
[TBL] [Abstract][Full Text] [Related]
55. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype.
Anorga S; Overstreet JM; Falke LL; Tang J; Goldschmeding RG; Higgins PJ; Samarakoon R
FASEB J; 2018 May; 32(5):2644-2657. PubMed ID: 29298862
[TBL] [Abstract][Full Text] [Related]
56. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
57. MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer.
Lee NH; Kim SJ; Hyun J
Biomedicines; 2021 Mar; 9(4):. PubMed ID: 33808155
[TBL] [Abstract][Full Text] [Related]
58. TAZ Controls
Tiffon C; Giraud J; Molina-Castro SE; Peru S; Seeneevassen L; Sifré E; Staedel C; Bessède E; Dubus P; Mégraud F; Lehours P; Martin OCB; Varon C
Cells; 2020 Jun; 9(6):. PubMed ID: 32545795
[No Abstract] [Full Text] [Related]
59. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma.
Zhao C; Gong J; Bai Y; Yin T; Zhou M; Pan S; Liu Y; Gao Y; Zhang Z; Shi Y; Zhu F; Zhang H; Wang M; Qin R
Cell Death Differ; 2023 Jan; 30(1):1-15. PubMed ID: 35906484
[TBL] [Abstract][Full Text] [Related]
60. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
